Concord Drugs logo

Concord Drugs financials and balance sheet

BSE: 538965Pharmaceuticals & BiotechnologySmall Cap

Last close ₹68.06down ₹0.94 (1.36%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹69.00.

52-week range of traded prices to 23 Oct 2026
₹61.00Low, 23 Oct 2025₹92.52High, 13 Nov 2025
Market cap
₹90 Cr3,001st largest listed
P/E
43.7
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROE
5.0%
ROCE
7.1%
Debt to equity
0.28
Volume, BSE
1,703

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Concord Drugs annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

The years either side of a change of basis do not compare. From the year to Mar 2025, the company's revenue for that year, ₹37 Cr, differs from its quarters added, ₹30 Cr.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue76
  2. Materials and goods−65
  3. Employee costs−4.9
  4. Other expenses−1.6
  5. Operating profit4.2
  6. Depreciation−1.4
  7. Other income0.0
  8. One-off items0.0
  9. Finance costs−1.5
  10. Profit before tax1.4
  11. Tax−0.4
  12. Net profit1.0

What the company owns

  • Receivables₹28 Cr
  • Plant, investments and other assets₹25 Cr
  • Inventory₹18 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹49 Cr
  • Borrowings₹12 Cr
  • Owed to suppliers₹6 Cr
  • Other liabilities₹6 Cr

Profit and loss

Standalone, ₹ crore, years to March.Concord Drugs quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 12 JunMar 2020Filed 29 JunMar 2021Filed 29 JunMar 2022Filed 14 JunMar 2023Filed 31 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 27 May
Revenue from operations57.551.848.151.351.459.051.343.336.975.8
52.047.044.448.048.153.447.039.633.271.6
Materials and goods bought46.143.339.642.642.242.140.933.327.665.1
Employee costs2.82.02.53.53.84.94.65.04.44.9
Other expenses3.11.72.31.92.26.41.51.31.11.6
Operating profit before depreciation5.54.83.73.33.25.64.33.73.84.2
Operating margin9.6%9.2%7.6%6.5%6.3%9.5%8.5%8.5%10.2%5.6%
Materials, % of revenue80.2%83.6%82.4%82.9%82.1%71.4%79.6%77.0%74.9%85.9%
Employee costs, % of revenue4.9%3.8%5.3%6.8%7.3%8.3%9.0%11.4%11.9%6.5%
Other expenses, % of revenue5.3%3.4%4.8%3.7%4.3%10.8%2.9%3.1%3.1%2.1%
Depreciation and amortisation2.62.41.71.51.41.81.61.51.41.4
Operating profit after depreciation2.92.41.91.91.93.82.72.12.32.9
Other income0.10.10.10.10.10.10.00.00.00.0
Finance costs2.41.91.61.51.41.71.61.61.71.5
Profit before one-off items and tax0.60.60.40.50.52.21.10.60.61.4
One-off items––0.00.03.80.00.00.00.00.0
Profit before tax0.60.60.40.54.32.21.10.60.61.4
0.50.30.00.11.00.70.20.10.30.4
Net profit0.20.30.40.33.31.60.90.40.31.0
Net margin0.3%0.6%0.8%0.6%6.4%2.7%1.7%1.0%0.8%1.4%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Filed 12 JunMar 2020Filed 29 JunMar 2021Filed 29 JunMar 2022Filed 14 JunMar 2023Filed 31 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 27 May
23.223.526.828.431.733.834.148.5
Share capital7.98.78.78.79.310.010.013.2
Reserves15.314.718.019.622.423.824.135.3
9.89.613.016.414.814.014.911.6
56.131.019.422.920.919.419.618.0
3.53.63.75.24.03.04.85.3
Total assets82.858.049.956.456.656.358.671.9
13.012.513.914.615.214.925.222.4
69.745.636.041.941.441.433.449.5
Net debt9.69.512.916.414.713.814.610.9
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Filed 29 JunMar 2022Filed 14 JunMar 2023Filed 31 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 27 May
1.60.82.22.03.2−7.4
2.11.42.62.23.4−6.9
−4.8−4.0−1.7−1.5−0.4−11.2
Receivables5.6−2.16.5−4.7−0.9−12.9
Inventories4.6−5.60.0−1.0−0.60.8
Payables−9.64.0−2.0−1.60.02.6
Other working capital−5.3−0.3−6.15.81.1−1.7
Tax paid−0.5−0.7−0.3−0.2−0.2−0.4
Capital spending3.72.50.91.02.31.2
Free cash flow−2.1−1.71.40.90.8−8.5
−3.7−2.4−2.3−1.2−2.3−1.1
2.11.70.1−0.7−0.98.7
Dividends paid0.00.00.00.00.00.0
Shares bought back0.00.00.00.00.00.0
Shares issued0.00.02.51.70.013.4
Net change in cash0.00.00.00.10.00.2
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Filed 12 JunMar 2020Filed 29 JunMar 2021Filed 29 JunMar 2022Filed 14 JunMar 2023Filed 31 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 27 May
Earnings per share₹0.22₹0.41₹0.52₹0.38₹3.75₹1.82₹0.96₹0.42₹0.30–
Diluted earnings per share₹0.22₹0.41₹0.52₹0.38₹3.75₹1.82₹0.96₹0.42₹0.30–
Book value per share––₹29.45₹26.86₹30.61₹32.44₹34.03₹33.82₹34.11₹48.51
Shareholder yield––––0.0%0.0%−10.2%−4.8%0.0%−19.0%
Market cap at the year end (₹ crore)42.220.016.511.525.425.424.035.231.170.2
Earnings per share is left blank for the year to Mar 2026: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Standalone, years to March.Concord Drugs PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 12 JunMar 2020Filed 29 JunMar 2021Filed 29 JunMar 2022Filed 14 JunMar 2023Filed 31 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 27 May
Revenue growth–−9.9%−7.2%6.8%0.0%14.8%−13.0%−15.7%–105.4%
Operating profit growth–−13.0%−23.6%−8.6%−3.7%73.7%−22.3%−15.3%–12.4%
Net profit growth–102.5%25.6%−19.3%899.7%−51.4%−44.0%−53.0%–250.8%
Earnings per share growth–86.4%26.8%−27.9%900.8%−51.5%−47.3%−56.3%––
––1.8%1.4%13.1%5.8%3.0%1.3%0.9%2.5%
–––−0.3 pts11.7 pts−7.3 pts−2.8 pts−1.7 pts−0.4 pts1.6 pts
From the net margin–––−0.4 pts12.7 pts−7.5 pts−2.1 pts−1.3 pts−0.2 pts0.6 pts
From asset turnover–––0.3 pts4.3 pts0.9 pts−0.7 pts−0.3 pts−0.2 pts1.2 pts
From borrowing–––−0.3 pts−5.3 pts−0.7 pts−0.1 pts−0.1 pts0.0 pts−0.2 pts
Return on capital employed––5.9%5.7%4.7%8.5%5.9%4.5%4.8%4.8%
Cash conversion––––49.2%48.6%251.6%467.3%1,069.7%−710.1%
Interest cover1.21.31.21.21.32.31.71.31.42.0
Debt to equity––0.420.410.480.580.470.410.440.24
Receivable days––368181147142116178125135
Inventory days––172141103152156203253103
Payable days––393110276246394534
Cash conversion cycle, days––147212223231227342333204
Working capital days––172165206204243302268195
Asset turnover––0.580.730.951.110.910.770.641.16
Assets per rupee of net worth––3.573.022.151.931.881.721.691.58
Sales per rupee of plant––4.355.273.894.424.203.943.206.95
Capital spending to depreciation––––2.691.390.530.661.650.86
Plant being built, % of plant in use––2.6%10.2%0.0%4.2%7.5%14.8%17.3%22.3%
Revenue growth, operating profit growth, net profit growth and earnings per share growth are left blank for the year to Mar 2025: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
1.6%
Cash from operations against operating profit
−174.1%
Measure10 years5 years3 years
Revenue growth, yearly rate–8.1%13.9%
Profit growth, yearly rate–−20.6%5.2%
Return on equity, average–2.7%1.6%
Return on capital employed, average–5.7%4.7%
Operating margin, average8.1%8.4%8.1%
Net margin, average1.6%1.5%1.0%
Asset turnover, average–0.920.86
Cash conversion cycle, days, average–267293
Interest cover, average1.51.71.6
Debt to equity, average–0.430.36

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations0.8−2.2−7.4
Cash from investing−9.4−4.7−1.1
Cash from financing8.87.18.7
Capital spending7.84.51.2
Dividends paid0.00.00.0
Shares bought back0.00.00.0
Shares issued for cash17.515.113.4
Borrowings raised0.00.00.0
Borrowings repaid9.24.93.2

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––8556––
Altman Z-scorePublished threshold 1.81––1.291.862.972.71––––
Beneish M-scorePublished threshold −1.78––––−2.75−2.43−1.97–––
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––9.886.141.61–––
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.801.71––
Receivables growth less revenue growthOur threshold 0 percentage points–––−54.25−18.58−4.52−15.49–––
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−19.39−26.8147.513.00–––
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––2.28−0.57−3.1911.64–––
Assets under construction, years of additionsOur threshold 2 years of additions–––7.160.000.291.88–––
Effective tax ratePublished threshold 17.16 per cent75.3149.307.4628.0923.5429.08––––
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−0.78––––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
21 Nov 2025CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleCrisil B-(Issuer Not Cooperating)Rating continues at the same levelStable5
21 Nov 2025CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleCrisil A4(Issuer Not Cooperating)Rating continues at the same level0.50
21 Nov 2025CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleCrisil B-(Issuer Not Cooperating)Rating continues at the same levelStable2.50
21 Nov 2025CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleCrisil B-(Issuer Not Cooperating)Rating continues at the same levelStable8.50
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.